Physician profile
Susan Pansing
NPI 1306816533
$34,862.56
in general payments reported to CMS, 2019-2025
49 companies · $879 in 2025
The $879 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,940 · 2020: $2,135 · 2021: $3,093 · 2022: $12K · 2023: $7,132 · 2024: $6,502 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,850 · Food and Beverage: $4,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,850.00 |
| Food and Beverage | $4,662.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,767.25 | 2019-2025 | |
| Allergan, INC. | $2,187.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,296.37 | 2019-2024 | |
| Biogen, INC. | $1,212.54 | 2019-2025 | Vumerity |
| Ucb, INC. | $1,049.10 | 2019-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $651.78 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Genzyme Corporation | $580.69 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $520.42 | 2019-2024 | Ultomiris |
| Emd Serono, INC. | $393.61 | 2019-2024 | Mavenclad |
| Neurocrine Biosciences, INC. | $339.07 | 2019-2023 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $336.04 | 2019-2025 | Nuplazid |
| Mdd US Operations, LLC | $323.29 | 2019-2025 | |
| Eisai INC. | $264.52 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $240.67 | 2019-2021 | |
| Amgen INC. | $207.92 | 2019-2023 | Aimovig |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Pansing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.